Premium
sPECAM‐1 in serum and CSF of acute ischaemic stroke patients
Author(s) -
Zaremba J.,
Losy J.
Publication year - 2002
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2002.01339.x
Subject(s) - cerebrospinal fluid , medicine , pathophysiology , stroke (engine) , inflammation , ischaemic stroke , ischemia , platelet , brain ischemia , immunology , mechanical engineering , engineering
Objectives – As platelet endothelial cell adhesion molecule‐1 (PECAM‐1) is one of key mediators of transendothelial migration of leucocytes during inflammation, and inflammatory reaction is observed in cerebral ischaemia, we decided to determine the levels of soluble PECAM‐1 (sPECAM‐1) in serum and cerebrospinal fluid (CSF) of patients with acute stroke. Material and methods – Twenty‐three patients with first‐ever in a lifetime completed ischaemic stroke have been studied. CSF and blood samples were obtained within 24 h of the onset of stroke and the levels of sPECAM‐1 in serum and CSF were quantified by ELISA. Results – Stroke patients displayed statistically significant higher levels of sPECAM‐1 in sera and CSF in comparison with control group. The levels were significantly higher in serum than in CSF, correlated between each other, and CSF sPECAM‐1 fraction was blood‐derived. Conclusion – Our results indirectly suggest that PECAM‐1 may play a role in the pathophysiological events during early phase of ischaemic stroke.